Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 23:13:51-52.
doi: 10.1016/j.ensci.2018.11.019. eCollection 2018 Dec.

Follow-on glatiramer acetate

Jeffrey A Cohen  1 , Christian Wolf  2 , Krzysztof Selmaj  3 , Roel Arends  4
Affiliations

Follow-on glatiramer acetate

Jeffrey A Cohen et al. eNeurologicalSci. .
No abstract available

Keywords: Biosimilars; Generics; Glatiramer acetate; Multiple sclerosis; Non-biological complex drugs.

PubMed Disclaimer

References

    1. Melamed-Gal S., Loupe P., Timan B. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci. 2018;12:19–30. - PMC - PubMed
    1. Cohen J.A., Belova A., Selmaj K.W. Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial. JAMA Neurol. 2015;72:1433–1441. - PubMed
    1. Selmaj K.W., Barkhof F., Belova A.N. Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. Mult. Scler. J. 2017;23:1909–1917. - PMC - PubMed
    1. Wolinsky J.S., Borresen T., Dietrich D. GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Mult. Scler. Relat. Disord. 2015;4:370–376. - PubMed
    1. Johnson K.P., Brooks B.R., Cohen J.A. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45:1268–1276. - PubMed

LinkOut - more resources